Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca : BEST OF THE BROKERS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/15/2017 | 07:21am CEST

Things are looking up for pharma giant Astrazeneca, Liberum analysts have said. Recent drug trials have driven the firm's shares back up to where they were before high-profile problems connected with the failure of lung cancer drug Imfinzi. Analysts downgrade the firm to a "hold" but hike Astra's target price to 5,000P.

Analysts from Cantor Fitzgerald praised home furnishings firm Dunelm for investing in growth over the last year. Such investment is paying dividends already, they say, with sales set to grow to over £2bn in the medium-term. Cantor brokers stick to their "buy" rating and target price of 780p.

(c) 2017 City A.M., source Newspaper

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
10/23DJEuropean Corporate Roundup for Monday
10/23 ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
10/23 ASTRAZENECA : US FDA Approves New Easy-to-Use, Once-Weekly BYDUREON® BCise&trade..
10/23DJEuropean Corporate Roundup for Monday
10/23 ASTRAZENECA : announces new data showing US preterm infants at significantly gre..
10/23DJASTRAZENECA : New Diabetes Drug Formulation Gets FDA Approval
10/23 ASTRAZENECA : AZ and MSD rapidly advance Lynparza in Japan
10/23 ASTRAZENECA : US FDA approves new easy-to-use, once-weekly Bydureon BCise inject..
10/23 ASTRAZENECA : and MSD rapidly advance Lynparza in Japan with a second regulatory..
10/23 ASTRAZENECA : US FDA approves Bydureon BCise for type-2 diabetes
More news
News from SeekingAlpha
10/23 BIG BIOTECH IN THE CRISPR GAME : Novartis And Vertex Lead The Pack
10/23 FDA OKs new formulation of AstraZeneca's diabetes med Bydureon
10/22 WEEK IN REVIEW : WuXi AppTec Acquires U.S.-Global Clinical CRO
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 19, 2017
Financials ($)
Sales 2017 21 638 M
EBIT 2017 5 959 M
Net income 2017 2 524 M
Debt 2017 12 193 M
Yield 2017 4,00%
P/E ratio 2017 30,76
P/E ratio 2018 25,99
EV / Sales 2017 4,55x
EV / Sales 2018 4,50x
Capitalization 86 178 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 66,4 $
Spread / Average Target -2,4%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA16.33%85 977
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223